Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FAST alone Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

NCT05117294
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteers
Interventions
Bocidelpar
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Anniston, Alabama • Rialto, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Not applicable Interventional Results available

Study Utilizing BIOZEK COVID-19 Antigen Rapid Test

NCT04926779
View directory record Official record
Conditions
Covid-19 Testing
Interventions
Biozek Covid-19 Antigen Rapid Test (Saliva)
Diagnostic Test
Lead sponsor
Mach-E B.V.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Flushing, New York • Southampton, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

NCT04707573
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 25, 2026, 11:24 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Renal Metabolism of Glycolate to Oxalate

NCT04437225
View directory record Official record
Conditions
Healthy
Interventions
Low oxalate controlled Diet, Primed, continuous intravenous infusion of 13C2-Glycolate, Bolus intravenous infusion of 13C2-Glycolate, Oral bolus administration of 13C2-Glycolate
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 25, 2026, 11:24 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

A Prospective, Single Center, Observational Study to Assess the Rapid Recovery After Cardiac Surgery Using SternaLock XP

NCT05578651
View directory record Official record
Conditions
Rigid Plate Fixation, Median Sternotomy
Interventions
SternaLock XP
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Fasting-Mimicking Diet on Skin Health

NCT05564624
View directory record Official record
Conditions
Skin
Interventions
Fasting mimicking diet (FMD)
Other
Lead sponsor
L-Nutra Inc
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)

NCT03108924
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Gefapixant
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Relative Bioavailability of Two Different Milk Thistle Formulations

NCT02529605
View directory record Official record
Conditions
Healthy
Interventions
Product B® IsaGenesis®, IsaGenesis®
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

NCT03943056
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB091, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Benazepril HCl 40 mg Tablets, Fed

NCT00836537
View directory record Official record
Conditions
Healthy
Interventions
Benazepril HCl 40 mg Tablets, Lotensin® 40 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers

NCT05995119
View directory record Official record
Conditions
Healthy Volunteers, Fasting, Fed
Interventions
Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)
Drug
Lead sponsor
TAHO Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 25, 2026, 11:24 AM EDT
Recruiting Phase 4 Interventional

Asciminib Roll-over Study

NCT04877522
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions
Asciminib single agent, Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib single agent pediatric formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
7 Years to 100 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

NCT03356639
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP6981, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Glendale, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Results available

Reoxygenation After Cardiac Arrest II (REOX II Study)

NCT02698826
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Protocol for rapid FiO2 optimization
Other
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jackson, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions

NCT00864526
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose, COMBONOX® tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

NCT00867685
View directory record Official record
Conditions
Healthy
Interventions
AZD2624
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Oct 25, 2026, 11:24 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants

NCT07618715
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Y-4 tablet, Pregabalin capsule, Riluzole tablet
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

NCT00838058
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Volunteers
Interventions
CE 224,535
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

NCT06860243
View directory record Official record
Conditions
Hepatic Impairment, Healthy Participants
Interventions
Opevesostat, Prednisone, Fludrocortisone acetate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Food Interaction Study of Seville Orange Juice and Colchicine

NCT00960193
View directory record Official record
Conditions
Healthy
Interventions
Colchicine, Seville Orange Juice
Drug · Other
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 25, 2026, 11:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

NCT02757326
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Opaganib
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

NCT01331421
View directory record Official record
Conditions
Breast Cancer
Interventions
exemestane
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

NCT01101321
View directory record Official record
Conditions
Healthy
Interventions
Reformulated OXY (Totowa) (oxycodone HCl), Reformulated OXY (Wilson) (oxycodone HCl)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects

NCT02223832
View directory record Official record
Conditions
Healthy
Interventions
ACT-128800
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 25, 2026, 11:24 AM EDT